New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 19, 2013
10:04 EDTETFC, SMS, VRTX, UBS, TOL, AN, NOK, NPTN, EWBC, OSTK, EE, AF, DXPE, BBT, TEF, MMSOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Astoria Financial (AF) upgraded to Market Perform from Underperform at Keefe Bruyette... Autonation (AN) upgraded to Hold from Sell at Deutsche Bank... E-Trade (ETFC) upgraded to Market Perform from Underperform at Keefe Bruyette... El Paso Electric (EE) upgraded to Buy from Hold at Jefferies... Maximus (MMS) upgraded to Outperform from Market Perform at Raymond James... Overstock.com (OSTK) upgraded to Buy from Underperform at BofA/Merrill... Toll Brothers (TOL) upgraded to Outperform from Market Perform at Keefe Bruyette... UBS (UBS) upgraded to Buy from Hold at Deutsche Bank... Vertex (VRTX) upgraded to Buy from Hold at Canaccord... Telefonica (TEF) upgraded at Bernstein... BB&T (BBT) upgraded to Buy from Neutral at Hilliard Lyons... East West Bancorp (EWBC) upgraded to Outperform from Market Perform at Keefe Bruyette... DXP Enterprises (DXPE) upgraded to Buy from Neutral at Ascendiant Capital... NeoPhotonics (NPTN) upgraded to Buy from Hold at Needham... Sims Metal (SMS) upgraded to Buy from Neutral at BofA/Merrill... Overstock.com (OSTK) upgraded at BofA/Merrill... Nokia (NOK) upgraded to Market Perform from Underperform at BMO Capital.
News For AF;AN;ETFC;EE;TOL;MMS;OSTK;UBS;TEF;EWBC;VRTX;BBT;NPTN;SMS;DXPE;NOK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 23, 2015
10:18 EDTVRTXVertex data not a surprise given recent commentary, says JPMorgan
JPMorgan said Vertex's VX-661 top-line Phase 2 data was generally below expectations but should not be too surprising given recent management commentary. The firm said its thesis remains unchanged and believes few biotechs offer a comparable level of competitive dominance and substantial earnings leverage as Vertex and reiterated its Overweight rating.
10:14 EDTVRTXVertex weakness a buying opportunity, says Piper Jaffray
Piper Jaffray said it views the Phase II study evaluating VX-661 in combination with ivacaftor in CF as too small and too short to derive meaningful conclusions and would use today's weakness following the data as a buying opportunity ahead of approval for KALYDECO + lumacaftor homozygous F508del-CFTR mutation patients, noting that the PDUFA date for the indication is July 5. The firm keeps an Overweight rating and $146 price target on Vertex shares, which are down 4.3% to $125.35 in morning trading.
09:38 EDTVRTXVertex shares defended at CRT Capital
Subscribe for More Information
09:37 EDTVRTXActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL AUY SLB PFE MCP CELG VRTX SHPG GILD LOGI TSLA TASR NFLX SCTY WFM
09:28 EDTVRTXOn The Fly: Pre-market Movers
Subscribe for More Information
09:03 EDTVRTXLeerink analysts hold a meeting with a conference call hookup
Subscribe for More Information
07:47 EDTVRTXVertex says VX-661, ivacaftor generally well tolerated in 12-week Phase 2 study
Vertex Pharmaceuticals announced data from a 12-week Phase 2 study evaluating VX-661 in combination with ivacaftor in 39 people with CF ages 18 and older who have two copies of the F508del mutation. The study evaluated two doses of VX-661 in combination with ivacaftor. The primary endpoint of the study was safety. The study showed that the combination regimen was generally well tolerated, and all patients completed 12 weeks of treatment. The most common adverse events were pulmonary exacerbation, which occurred in 38% of all patients who received VX-661 and 44% of those who received placebo, and cough, which occurred in 33% of all patients who received VX-661 and 39% of those who received placebo. Secondary endpoints evaluated the effect of the combination on lung function, and the mean within-group absolute improvement from baseline in ppFEV1 for those who received 100 mg of VX-661 in combination with ivacafto was 4.4 and 3.0 percentage points at week 4 and through 12 weeks of treatment, respectively. Consistent with prior Phase 2 studies that evaluated 4 weeks of treatment with VX-661 in combination with ivacaftor, this study showed a rapid improvement in lung function within four weeks of treatment, and after patients completed treatment, lung function returned to baseline. These safety and efficacy data, together with other data from multiple previously completed Phase 2 studies of VX-661, support Vertex’s ongoing Phase 3 program of VX-661 in combination with ivacaftor. The Phase 3 program is evaluating VX-661 in combination with ivacaftor and consists of four Phase 3 studies, including a study in people with two copies of the F508del mutation that began enrollment in February. The other three studies will enroll people with CF who have one copy of the F508del mutation and a second mutation that is either a gating mutation, residual function mutation or a mutation that results in minimal CFTR function.
06:21 EDTUBSUBS in discussions to lease space from RBS in Connecticut, WSJ reports
Subscribe for More Information
06:10 EDTTEFBT Group plans to announce BT Mobile 4G network this week, Telegraph reports
BT Group (BT) is said to be planning to announce the launch of its own 4G network this week, The Telegraph reports. The service, BT Mobile, will initially be offered to the company's 7.6M broadband subscribers and will compete with offerings from O2 (TEF) and Vodafone (VOD). Reference Link
March 20, 2015
10:00 EDTMMSOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:47 EDTTOLToll Brothers management to meet with Deutsche Bank
Subscribe for More Information
05:36 EDTMMSMaximus initiated with an Outperform at Wells Fargo
Subscribe for More Information
March 19, 2015
07:36 EDTTOLToll Brothers management to meet with Deutsche Bank
Meeting to be held in Frankfurt on March 19 hosted by Deutsche Bank.
March 18, 2015
07:39 EDTTOLToll Brothers management to meet with Deutsche Bank
Meetings to be held in Geneva/Zurich on March 18 hosted by Deutsche Bank.
07:20 EDTUBSU.S. considers 'tearing up' non-prosecution deals with banks, Bloomberg says
Subscribe for More Information
07:18 EDTETFCWells Fargo to hold a forum
Subscribe for More Information
March 17, 2015
14:37 EDTUBSCiti, Barclays near $800M settelement of forex suit, WSJ says
Subscribe for More Information
10:42 EDTBBTBB&T remains an underappreciated story, says BofA/Merrill
BofA/Merrill reiterated its Buy rating and $44 price target on BB&T and said it remains an underappreciated and under-owned. The firm notes BB&T is using excess capital and currency strength to return capital to shareholders and pursue accretive deals. BofA/Merrill thinks the Susquehanna deal could prove more beneficial than the market perceives and its excess liquidity position makes it more rate sensitive versus peers. Shares are Buy rated with a $44 price target.
March 16, 2015
14:08 EDTUBSEU regulator says time for fine-tuning, Reuters says
The Basel Committee on Banking Supervision believes the necessary bank regulatory framework is in place though some additional work must be done to finalize leverage ratio and capital floor rules, Reuters reported yesterday, citing statements by secretary-general William Coen at a financial conference in Doha. Coen added, "We're now at the state where we can take a step back and look to see how [the regulations] fit together," cautioning that further analysis must be data-driven but admitting that both banks and regulatory bodies were feeling "regulation fatigue." Publicly traded companies in the space include Banco Santander (SAN), Barclays (BCS), Credit Suisse (CS), Deutsche Bank (DB), HSBC (HSBC), ING Groep (ING), Lloyds Banking (LYG), RBS (RBS) and UBS (UBS). Reference Link
12:56 EDTDXPEDXP Enterprises management to meet with Sidoti
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use